Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Female, 18+, with evaluable metastatic breast cancer and stable brain metastases~* Must have received definitive radiotherapy~* No evidence, or history of, central nervous system hemorrhage~* Adequate organ and hematological function~Exclusion Criteria:~* Active infection, non-healing wound, or history of any bleeding diathesis or coagulopathy~* Uncontrolled hypertension, congestive heart failure, peripheral vascular disease

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab / Capecitabine (Type: ACTIVE_COMPARATOR): Bevacizumab 15 mg/kg every 3 weeks in combination with Capecitabine (Xeloda), 2 weeks on and 1 week off on a every 3 week cycle.
- Bevacizumab / Docetaxel (Type: ACTIVE_COMPARATOR): Docetaxel (taxotere) 35mg/m² IV over 60 min days 1, 8, and 15 in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.
- Bevacizumab /Irinotecan (Camptosar®, CPT-11) (Type: ACTIVE_COMPARATOR): CPT-11 (Irinotecan, Camptosar) - Patients being treated with an enzyme inducing antiepileptic drug (EIAED) will receive 340 mg/m² IV; others will receive 125 mg/m² IV 90 min on days 1 and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.
- Bevacizumab / Paclitaxel (Type: ACTIVE_COMPARATOR): Paclitaxel (Taxol)90 mg/m2 IV over 60-90 min days 1, 8, and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.
- Bevacizumab /Vinorelbine Tartrate (Type: ACTIVE_COMPARATOR): Vinorelbine Tartrate (Navelbine®) 25 mg/m² IV over 10 min days 1, 8 and 15 in combination with avastin 10 mg/kg IV on days 1 and 15 of a 28-day cycle.
- Bevacizumab / Gemcitabine (Type: ACTIVE_COMPARATOR): Gemcitabine (difluorodeoxycytidine, dFdC) 1000 mg/m2 IV on days 1 and 8 in combination with avastin 15 mg/kg IV on day 1 of a 21-day treatment cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).